ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 177.9 DKK 1.02% Market Closed
Market Cap: 36B DKK

ALK-Abello A/S
Investor Relations

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets.

The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

Show more
Loading
ALK B
OMX Copenhagen 25

Earnings Calls

2024 Q3
Nov 14, 2024
Show Transcript
Previous
Next
ALK's Q3 Highlights: Strong Growth and Positive Outlook
2024 Q3
Nov 14, 2024

ALK delivered an impressive Q3, achieving 18% organic revenue growth, primarily fueled by a 29% global increase in tablet sales. The EBIT margin improved significantly from 13% to 23% year-on-year, aided by higher sales and cost efficiencies. The company confirmed a full-year revenue growth outlook of 14% to 16% and an EBIT margin of 19% to 21%. Notably, ALK has ventured into new markets with a major licensing deal for the neffy nasal spray, projected for significant future growth. Key product launches for pediatric with the house dust mite tablet are expected late 2024, positioning ALK for continued long-term success.

Show Full Analysis

Management

Mr. Claus Steensen Solje
Executive VP, CFO & Member of Management Board
No Bio Available
Mr. Søren Daniel Niegel
Executive VP of Commercial Operations & Member of Management Board
No Bio Available
Dr. Henriette Mersebach
Executive VP Research & Development & Member of Management Board
No Bio Available
Ms. Katja Barnkob Thalund
Project Director of Global CMC Development & Employee-elected Director
No Bio Available
Ms. Lise Lund Maerkedahl
Project Director of Global Research & Employee-elected Director
No Bio Available
Mr. Peter Halling
President & CEO
No Bio Available
Mr. Per Plotnikof
VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
No Bio Available
Jacob Glenting
Senior Vice President of Global Strategy & Corporate Development
No Bio Available
Ms. Lika Thiesen
Executive Vice President of Global People & Organisation
No Bio Available
Prof. Hendrik Kees Kam Nolte M.D., Ph.D.
Senior Vice President of Research & Development - North America and International Markets
No Bio Available

Contacts

Address
Hoersholm
Boege Alle 6-8
Contacts
+4545747576.0
www.alk.net